Connected With Latham

In each episode of Connected With Latham, we discuss ideas, developments, and trends shaping the global economy.

Episode 98 – Drug Pricing: Takeaways from the MDMA Annual Meeting
Jun 6, 2025 – 40:21
Episode 97 – Drug Pricing: How the Drug Pricing EO Impacts FDA and Overlaps with Grassley-Led Legislation
May 2, 2025 – 50:18
Episode 96 – The Growth Rocketship: Shield AI’s Takeoff Shows What’s Possible in Defensetech
Apr 30, 2025 – 52:23
Episode 95 – Drug Pricing: FDA in the Age of Executive Orders and DOGE
Mar 12, 2025 – 22:14
Episode 94 – Drug Pricing: 2025 J.P. Morgan Healthcare Conference Takeaways and Outlook
Feb 25, 2025 – 22:13
Episode 93 – EU’s Digital Operational Resilience Act: What You Should Know and How to Stay Compliant
Jan 16, 2025 – 19:34
Episode 92 – UK FinReg Focus Areas in 2025: Sectoral Trends
Jan 6, 2025 – 29:45
Episode 91 – UK FinReg Focus Areas in 2025: Retail Markets
Jan 6, 2025 – 20:32
Episode 90 – UK FinReg Focus Areas in 2025: Wholesale Markets
Jan 6, 2025 – 23:23
Episode 89 – The Growth Rocketship: How BridgeBio’s Hub and Spoke Portfolio Strategy Set the Market for the Future of Biotech – Then, Now, and What’s Next?
Dec 30, 2024 – 47:21
Episode 88 – Drug Pricing: How Might the Trump Administration Transform FDA Enforcement Activities?
Dec 16, 2024 – 33:12
Episode 87 – Drug Pricing: What’s In the New CMS Medicaid Final Rule?
Nov 25, 2024 – 28:38
Episode 86 – Drug Pricing: Takeaways from the Chicago Medicaid Drug Rebate Program Summit
Oct 18, 2024 – 18:25
Episode 85 – Drug Pricing: How The Demise of Chevron Deference and Other Litigation May Impact the Pharmaceutical Industry
Sep 19, 2024 – 21:48
Episode 84 – Pro Bono: Shabir Kabiri’s Remarkable Journey from Afghanistan to Asylum in the US
Aug 20, 2024 – 34:22
Episode 83 – Drug Pricing: How Are Payers Responding to the IRA?
Aug 19, 2024 – 29:16
Episode 82 – Drug Pricing: Takeaways from the New Orleans Pricing and Contracting USA Conference
Jun 21, 2024 – 17:31
Episode 81 – Drug Pricing: A Look Behind the Curtain of the New ASP Reporting Website and Other Data Collection Portals
Jun 13, 2024 – 23:35
Episode 80 – Energy & Infrastructure: Why is Energy Tech So Attractive to Venture Capital?
Jun 10, 2024 – 26:13
Episode 79 – Pro Bono: Rewilding the Scottish Highlands Through Forest Restoration
Apr 16, 2024 – 16:03
Episode 78 – UK FinReg Focus Areas in 2024: ESG
Mar 8, 2024 – 17:12
Episode 77 – UK FinReg Focus Areas in 2024: Enforcement Against Individuals
Mar 5, 2024 – 08:23
Episode 76 – UK FinReg Focus Areas in 2024: Regulatory Divergence
Feb 29, 2024 – 17:49
Episode 75 – UK FinReg Focus Areas in 2024: Enforcement Against Firms
Feb 23, 2024 – 13:24
Episode 74 – UK FinReg Focus Areas in 2024: Conduct and Culture
Feb 19, 2024 – 13:19
Episode 73 – UK FinReg Focus Areas in 2024: Artificial Intelligence
Feb 8, 2024 – 13:54
Episode 72 – UK FinReg Focus Areas in 2024: The Edinburgh Reforms
Feb 2, 2024 – 10:18
Episode 71 – Drug Pricing: A Look Ahead at Trends for 2024
Feb 1, 2024 – 11:48
Episode 70 – UK FinReg Focus Areas in 2024: Investment Research
Jan 31, 2024 – 17:14
Episode 69 – UK FinReg Focus Areas in 2024: Retail Markets – Direction of Travel
Jan 26, 2024 – 13:49
Episode 68 – Drug Pricing: Will Agencies Exercise March-In Rights Based on Drug Price?
Jan 25, 2024 – 13:39
Episode 67 – PE Views: The Most Pressing Cybersecurity Considerations For Private Equity
Jan 23, 2024 – 33:59
Episode 66 – UK FinReg Focus Areas in 2024: Primary Markets Reform
Jan 19, 2024 – 13:54
Episode 65 – PE Views: How Can PE Sponsors Promote Transparency and Successful Fund Raise Amid ESG Scrutiny?
Dec 20, 2023 – 09:51
Episode 64 – Energy & Infrastructure: How Can Companies Avoid Greenwashing Allegations and ESG Litigation Risks?
Dec 18, 2023 – 25:52
Episode 63 – M&A Views: How Should Deal Teams Navigate a Global Crackdown on Restrictive Covenants?
Dec 14, 2023 – 13:57
Episode 62 – Has FDA Meaningfully Changed Its Restrictions on Off-Label Communications?
Dec 13, 2023 – 26:26
Episode 61 – Drug Pricing: New OIG Guidance Reaffirms the Seven Elements of an Effective Compliance Program
Dec 7, 2023 – 12:45
Episode 60 – PE Views: Is the CMA’s Focus on Roll-Up Transactions Here to Stay?
Nov 10, 2023 – 10:28
Episode 59 – SCOTUS Update: Perez v. Sturgis Secures a Supreme Court Win for Disability Rights
Nov 2, 2023 – 37:08
Episode 58 – FDI Developments: M&A Security Screening in Europe's Fragmented FDI Landscape
Oct 24, 2023 – 19:36
Episode 57 – Drug Pricing: What Trends Emerged from the 2023 Medicaid Drug Rebate Program Summit?
Oct 20, 2023 – 12:12
Episode 56 – M&A Views: Avoiding Buyer’s Remorse in M&A Deals
Sep 27, 2023 – 13:25
Episode 55 – Insurtech: What Should Startups Do After Receiving FCA Authorization?
Sep 21, 2023 – 08:37
Episode 54 – Drug Pricing: Focus on Best Price — CMS Proposed Rule, Inflation Reduction Act
Sep 15, 2023 – 13:17
Episode 53 – Energy & Infrastructure: Can Sustainable Finance Fuel the Energy Transition?
Aug 30, 2023 – 18:05
Episode 52 – Drug Pricing: Could a Single Reference Price Apply Across a Therapeutic Class?
Aug 21, 2023 – 11:16
Episode 51 – Drug Pricing: Final IRA Price Negotiation Guidance – How CMS Addressed the Part D/B Problem
Jul 31, 2023 – 10:53
Episode 50 – PE Views: Under New Reforms, Is the Customer Always Right?
Jul 14, 2023 – 12:48
Episode 49 – PE Views: Will Greenwashing Rain on the UK PE Parade?
Jun 20, 2023 – 17:29